Tandem Diabetes Care (MEX:TNDM) Cash Flow from Financing : MXN182 Mil (TTM As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Tandem Diabetes Care Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Jun. 2024, Tandem Diabetes Care paid MXN0 Mil more to buy back shares than it received from issuing new shares. It received MXN0 Mil from issuing more debt. It paid MXN0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received MXN0 Mil from paying cash dividends to shareholders. It received MXN0 Mil on other financial activities. In all, Tandem Diabetes Care spent MXN0 Mil on financial activities for the three months ended in Jun. 2024.

Tandem Diabetes Care Cash Flow from Financing Historical Data

The historical data trend for Tandem Diabetes Care's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tandem Diabetes Care Cash Flow from Financing Chart

Tandem Diabetes Care Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

Get a 7-Day Free Trial

456.54

6,254.80

1,065.33

329.03

69.82

Tandem Diabetes Care Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Cash Flow from Financing	Get a 7-Day Free Trial															67.68	-33.29	44.42	225.48	-55.00

Tandem Diabetes Care Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Tandem Diabetes Care's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0

Tandem Diabetes Care's Cash from Financing for the quarter that ended in Jun. 2024 is:

	Cash Flow from Financing		(Q: Jun. 2024 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0

Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN182 Mil.

Tandem Diabetes Care (MEX:TNDM) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Tandem Diabetes Care's issuance of stock for the three months ended in Jun. 2024 was MXN0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Tandem Diabetes Care's repurchase of stock for the three months ended in Jun. 2024 was MXN0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Tandem Diabetes Care's net issuance of debt for the three months ended in Jun. 2024 was MXN0 Mil. Tandem Diabetes Care received MXN0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Tandem Diabetes Care's net issuance of preferred for the three months ended in Jun. 2024 was MXN0 Mil. Tandem Diabetes Care paid MXN0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Tandem Diabetes Care's cash flow for dividends for the three months ended in Jun. 2024 was MXN0 Mil. Tandem Diabetes Care received MXN0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Tandem Diabetes Care's other financing for the three months ended in Jun. 2024 was MXN0 Mil. Tandem Diabetes Care received MXN0 Mil on other financial activities.

Tandem Diabetes Care Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Tandem Diabetes Care's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Tandem Diabetes Care Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tandem Diabetes Care Inc (MEX:TNDM) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

TNDM:USA 0M0F:UK TD5A:Germany

Address

12400 High Bluff Drive, San Diego, CA, USA, 92130

Website

https://www.tandemdiabetes.com

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.